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Abstract: Postpartum haemorrhage (PPH) is a major killer of women 
worldwide. Its initial treatment has largely been reliant on uterotonics. 
This paper examines the use of histograms to assess the efficacy of 
uterotonic treatment for PPH. The main aim was to explore whether post 
treatment peaks are routinely seen in postpartum blood loss histograms 
and whether the peaks are only seen in treated women. This is secondary 
data analysis using histogram. It has been noted that the presence of 
secondary peak was not only seen in treated cases. A secondary peak was 
noted in many of the histograms and includes many women who did not 
receive uterotonic treatment. Many women received treatment despite 
having blood loss of under 500 mls, and many women who stopped bleeding 
with final blood losses of over 500 mls did not receive any uterotonics.  
So the routine use of histogram analysis to assess the efficiency of 
uterotonic therapy is not recommended. The paper provides further 
insights into clinical practice, with clinicians frequently using 
uterotonic therapies even when the volume of the blood loss is low. This 
demonstrates how uterotonic use in practice is often not linked with the 
standard 500 mls definition of postpartum haemorrhage. 
 
 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
THE USE OF HISTOGRAMS TO ASSESS THE EFFICACY 
OF UTEROTONIC TREATMENT FOR POSTPARTUM 
HAEMORRHAGE: A FEASIBILITY STUDY. 
Nasreen B Aflaifel1, 2, Nomita Chandhiok3, Bukola Fawole4, Stacie E Geller5 and 
Andrew D Weeks1. 
 
1. Sanyu Research Unit, University Department of Women’s and Children’s Health 
Liverpool Women's Hospital, Liverpool, UK. 
2. Department of Obstetrics and Gynaecology, University of Omar Al Mukhtar, Al 
Bida, Libya 
3. Division of Reproductive Health and Nutrition, Indian council of medical research, 
New Delhi, India 
4. Department of Obstetrics and Gynaecology, University College Hospital, Ibadan, 
Nigeria  
5. Department of Obstetrics and Gynecology, University of Arizona, Chicago,USA. 
Corresponding author: Professor Andrew Weeks, Professor of International 
Maternal Health 
Email: aweeks@liverpool.ac.uk, Tel: 0151 7959578, Fax: 0151 7959599 
Sanyu Research Unit, University Department of Women’s and Children’s Health, 
Liverpool Women's Hospital, Crown Street, Liverpool L8 7S 
Word count: 4738 
 
*Manuscript
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Abstract 
 
Postpartum haemorrhage (PPH) is a major killer of women worldwide. Its initial 
treatment has largely been reliant on uterotonics. This paper examines the use of 
histograms to assess the efficacy of uterotonic treatment for PPH. The main aim was 
to explore whether post treatment peaks are routinely seen in postpartum blood loss 
histograms and whether the peaks are only seen in treated women. This is 
secondary data analysis using histogram. It has been noted that the presence of 
secondary peak was not only seen in treated cases. A secondary peak was noted in 
many of the histograms and includes many women who did not receive uterotonic 
treatment. Many women received treatment despite having blood loss of under 500 
mls, and many women who stopped bleeding with final blood losses of over 500 mls 
did not receive any uterotonics.  So the routine use of histogram analysis to assess 
the efficiency of uterotonic therapy is not recommended. The paper provides further 
insights into clinical practice, with clinicians frequently using uterotonic therapies 
even when the volume of the blood loss is low. This demonstrates how uterotonic 
use in practice is often not linked with the standard 500 mls definition of postpartum 
haemorrhage. 
Keywords: Postpartum haemorrhage, Treatment, additional uterotonic, histogram 
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Introduction  
Postpartum haemorrhage (PPH) is a major killer of women worldwide, but its 
treatment has largely been developed empirically. Given that an atonic uterus is 
thought to be the most common cause of PPH, the standard management of PPH 
starts with the administration of a dose of uterotonic, even if the mother has received 
prophylaxis. There is little evidence behind this treatment strategy, but the finding 
that prophylactic uterotonics markedly reduce both the mean blood loss and rates of 
PPH (1-3) justifies the use of uterotonics as a first line treatment option. Recent 
research has shown that a single dose of misoprostol 800 mcg administered 
sublingually can be used for atonic PPH in women who have received oxytocin 
prophylaxis, as well as those who have received no oxytocin prophylaxis (4, 5). It is 
not known, however, whether oxytocin treatment has benefits over placebo alone 
due to the ethical imperative to provide treatment for all women. Furthermore, recent 
evidence from double-blind randomized controlled trials (RCTs) suggests that 
concurrent treatment with two drugs (i.e. misoprostol in addition to oxytocin, or an 
oxytocin infusion in addition to an oxytocin bolus) has little or no benefit.(6, 7) A 
question remains therefore over the absolute efficacy of uterotonic therapies. 
The technique of evaluating the effect of an intervention by measuring the size of a 
post-intervention response in continuously collected data is widely used in laboratory 
experiments, but rarely in epidemiology. With accurate measurement of blood loss 
the same principles can be applied to large blood loss datasets where the response 
to uterotonic treatment is seen on blood loss histograms as a post treatment peak. 
This represents the number of mothers who responded immediately to treatment. 
This method was used in a recent secondary analysis of 2 large randomized trials, 
(4, 5) where Weeks and others measured the size of the post-treatment peaks to 
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compare the effect of misoprostol and placebo on women who had received oxytocin 
prophylaxis or none (8). It is not known whether this data can be replicated in other 
data sets, or whether the same attenuation of efficacy is seen with other uterotonics. 
We therefore explored the data sets from large randomized studies with measured 
postpartum blood loss in which participants have been managed according to an 
explicit protocol for the prophylaxis and treatment of PPH.  
Materials and methods 
This study sought to examine the databases of all clinical trials of postpartum 
haemorrhage prophylaxis of over 1000 women which included individual patient data 
on measured blood loss, type of prophylaxis used and type of treatment used. 
In order to identify suitable studies, we searched the Cochrane library database 
including Cochrane Central of Controlled Trials (CENTRAL), Embase, Ovid version 
of Medline, Web of knowledge and Scopus for relevant RCTs, using different 
keywords and medical subject headings (MeSH) without language restrictions. 
Examples of used MeSH and keywords are postpartum haemorrhage, any 
intervention used for PPH prevention such a oxytocin, ergometrine, misoprostol, 
carbetocin, oxytocin analogues, prostaglandin. Wildcards were used to improve the 
search sensitivity.  
Titles and abstracts of 4170 papers were identified initially; removal of duplicates 
resulted in 1975 articles. Several types of studies were assessed as ineligible for 
inclusion, such as research on cost effectiveness or hemodynamic effect of drugs or 
the assessment of drug side effects within population. Conference abstracts, non-
randomized, observational and retrospective studies were also not included. Further 
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exclusion left 125 papers for review. Nineteen fulfilled the study inclusion criteria 
described above. These studies’ principal investigators were contacted by email to 
request their original data for secondary reanalysis. The protocol of the study was 
emailed to those who initially agreed to participate, and the datasets from 4 studies 
were obtained for analysis. The data set for each randomized trial was divided into 
groups according to the type of prophylaxis used. The reported final blood loss for 
each woman was categorized into 100 mls increments from 0-2000 mls, according to 
the definition of PPH in the included studies, and then graphically displayed in a 
histogram. The percentage of women in every increment was obtained by divided 
the number of women in each increment by the total number of women within the 
study arm from which women where extracted. This process was repeated for each 
group. 
In order to assess whether the peaks seen in the histogram had occurred as a result 
of the treatment administered, a second graph was also produced containing only 
the data for those women who received treatment with a uterotonic. This allowed an 
assessment of whether any fluctuation in the histogram was due to uterotonic 
treatment. Women with missing data on total blood volume were excluded.  
All studies received ethical approval prior to recruitment to the individual randomised 
trials and the data upon which this analysis was based had already been published. 
No further ethical approval was therefore sought for this additional analysis of data. 
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Results  
All of the included studies compared prophylactic misoprostol (either alone or in 
addition to other uterotonic) with another uterotonic or placebo in women having a 
vaginal birth. Two of the included studies were conducted in primary health care 
centers in India and compared 600mcg of oral misoprostol either with ergometrine 
(9) or with placebo (10), in low risk women. The two other trials were placebo-
controlled, double-blind trials which examined the effect of the additional 
administration of 400 mcg of sublingual misoprostol to a routine prophylactic 
uterotonic. One was conducted in Nigeria (11) and the other was multi-country (12).  
 
1. Chandhiok , 2006 (9) 
Chandhiok and colleagues (9) investigated whether oral misoprostol administered by 
paramedical workers from rural primary health centers in India, was effective at 
preventing PPH. The researchers used prophylaxis with 600 mcg misoprostol or 
ergometrine in low risk women undergoing vaginal delivery. The blood loss was 
collected and measured for 1 hour after delivery (or 2 hours for those bleeding was 
persisting). In this study, there was a low incidence of PPH (<1%) in both groups, but 
a significant reduction was noticed in median blood loss after delivery (100 mls vs. 
200 mls; p < 0.001) in the misoprostol arm (Figure 1). In the misoprostol 2 small 
peaks were seen consisting of 4 women who treated with uterotonic. The first peak 
was at a total blood loss 600-900 mls and the other was at 1200-1300 mls (Figure 2). 
In the methergine group, 4 women were diagnosed with PPH and of these, only 2 
women received treatment. Two others, with a total blood loss between 600 and 
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800mls, did not receive a uterotonic but stopped bleeding spontaneously (Figure 3). 
The treatment peaks of similar size were noted in misoprostol and methergine 
groups.  
In this study, very few women had a PPH, and all settled quickly with maximum 
blood loss of 1200-1300 ml. No women with a blood loss of < 500 mls received 
treatment and almost all those diagnosed with PPH had treatment. 
2. Derman, 2006 (10) 
The second study was a RCT conducted by Derman and co-workers (10). This was 
a placebo-controlled trial of 600 mcg oral misoprostol for the prevention of PPH 
conducted in rural India. Oral misoprostol was associated with a significant reduction 
in the rate of PPH ≥ 500 mls (12.0% to 6.4%, p < 0.0001) and severe PPH ≥ 1000 
mls (1.2% to 0.2%, p < 0.0001). Misoprostol was also associated with a decrease in 
mean postpartum blood loss (262.3 mL to 214.3 mL, p < 0.0001). This is shown 
graphically in the histogram figure 4. 
Despite the frequency of PPH in both study groups (6.4% in the misoprostol group 
and 12.0% in placebo group), very few women with PPH received treatment (2 in 
misoprostol group and 6 in the placebo arm). In addition, some women with blood 
loss < 500 mls received treatment (Figures 5 & 6). In the misoprostol arm, both 
treated women had final blood losses of under 500 mls, whilst all of those with a 
PPH of over 500 mls stopped bleeding spontaneously without receiving further 
uterotonic therapy. In the placebo arm, one woman received treatment despite a final 
blood loss of only 200mls (200<300). The remaining 5 treated women all had blood 
losses of over 500mls. However, of 97 women with PPH in the placebo arm, only 5 
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women (5%) required treatment – the remainder stopped spontaneously without the 
need for oxytocic therapy. 
3. Hofmeyr and Fawole (11,12) 
The two final studies compared the use of misoprostol and placebo in addition to 
routine uterotonic prophylaxis (11, 12). These two studies were double-blind, 
placebo-controlled multicenter randomized trials undertaken in hospitals to 
investigate the administration of 400 mcg sublingual to augment routine active 
management of the third stage of labour to prevent PPH. In both studies the 
measurement of blood loss was for one hour after delivery. Neither trial found any 
significant difference in the primary outcome of blood loss of 500 mls or more within 
1 hour of randomization: misoprostol 40 [6.1%] versus placebo 42 [6.4%] (11) and 
misoprostol 22 [4.0%] versus placebo 35 [6.3%] (12). This can be also seen 
graphically in the histograms in figures 7 and 10. 
In both studies, the majority of women who received treatment had blood losses of 
under 500ml (Figures 8, 9, 11 and 12). As with the previous studies, small secondary 
peaks were seen in all study arms, despite many women within the secondary peaks 
not having received uterotonic therapy. 
 
Comment 
This exploratory study examined the distribution of blood loss for women during the 
third stage of labour using histograms. All of the included studies compared the 
prophylactic effect of oral or sublingual misoprostol (either alone or in addition to 
routine uterotonic) with placebo or another uterotonic in preventing PPH during 
vaginal birth.  
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The only previous description of this methodology is a study examining the data from 
2 large randomized trials conducted by Gynuity Health Projects in which 40,403 
women were recruited and had intrapartum blood loss measured. Those with blood 
loss over 700 mls were randomized to receive 800 mcg sublingual misoprostol or 40 
IU intravenous oxytocin. In a secondary analysis similar to this one, no peak was 
seen for non-treated cases, but clear peaks were measurable for those who received 
either oxytocin or misoprostol (8). The size of the treatment peak was attenuated by 
the use of oxytocin prophylaxis. The data analyzed here is from smaller studies 
which were examining the effect of prophylaxis on blood loss. The time of initiating 
treatment was left to the clinical team and the histograms thus represent “real life” 
care. Whilst it cannot be stated that the uterotonic treatment was given immediately 
before bleeding stopped, the final blood loss represents the latest point at which it 
could have been given. The treatment graphs are therefore conservative examples, 
representing the highest blood loss at which uterotonic treatment could have been 
used. This is in contrast to the Gynuity PPH management studies,. In those, there 
were rigorous diagnostic and treatment protocols which were necessary because 
they were specifically examining PPH treatment, and so the accuracy of the 
diagnosis, randomization and initiation of treatment were critical.  
An important finding from this study is that presence of a peak was not specific for 
treated cases. A secondary peak was noted in many of the histograms and contains 
many women who did not receive uterotonic treatment. In the Chandhiok study for 
example the group who received ergometrine for prophylaxis but did not receive any 
treatment still had a secondary peak at a blood loss of around 600-800 mls (Figure 
3). This could reflect the effect of other therapies rather than uterotonics in treating 
PPH such as bimanual uterine compression or/and uterine massage. The presence 
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of this peak should caution against the over-interpretation of histogram data and 
ascribing the presence of treatment peaks to uterotonics alone. 
Although postpartum blood loss was objectively measured in all of the included 
studies, the use of oxytocic therapy was not consistent with the use of therapy only 
at the traditional blood loss cut off of 500 mls. In the studies of Fawole (11) and 
Hofmeyr (12) the vast majority of uterotonic therapy was given to women with a final 
blood loss of under 500 mls. This reflects reality, where the decision to initiate 
therapy is based not only on the volume of blood lost, but also on the speed of the 
blood flow, the underlining cause of the bleeding and the woman’s clinical condition. 
This was also highlighted in a review on postpartum blood loss estimation (13). Thus 
a severely anemic woman with a prolonged labour who has a gush of blood 
postnatally would rightly be given treatment immediately, even though the final blood 
loss might amount to only 100 mls in total. Although this reflects usual practice, it 
limits the use of the histogram analysis to studies with a very clear and rigorously 
enforced protocol for the uterotonics use. 
Of more concern is the number of women who bled over 500 mls but did not receive 
uterotonic therapy. This again reflects clinical practice where underestimation of 
blood loss is common, especially if the woman is otherwise healthy, and there is a 
slow trickle of blood thought to be coming from vaginal lacerations. This surprise 
finding provides a fascinating insight into clinical practice in PPH treatment. 
The implications of these findings are that: a) in prophylaxis trials, the rate of 
uterotonic use appears to be a poor surrogate for PPH; b) the recommendations to 
treat PPH at 500 mls may not be commonly used in clinical practice and need to be 
reviewed; and c) the size of the histogram “treatment peaks” are not a good indicator 
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of the efficiency of uterotonics, unless the clinicians follow a very strict treatment 
protocol (which may not reflect clinical practice). 
Furthermore, it appears that vaginal blood loss in women having a PPH usually 
stops and frequently does so even without uterotonic therapy. A change in direction of 
future research is required to explore these in more detailThis presents a dilemma for 
clinicians. Whilst reassuring, it is impossible to predict who will spontaneously stop 
bleeding and who will continue bleeding to life-threatening levels. In addition, PPH 
causes significant problems through postpartum anaemia and the use of uterotonics 
is likely to hasten the cessation of bleeding. Understandably therefore, clinicians 
tend to use uterotonics frequently and at very early stages to prevent progression. 
Summary 
The findings from this study do not support the routine use of histogram analysis to 
assess the efficiency of uterotonic therapy. The analysis of histograms should be 
limited to PPH treatment studies in which strict protocols are used for the timing and 
nature of PPH treatment. Even then, the finding of a secondary peak in untreated 
women in these studies should warn against ascribing all the effect to uterotonic 
therapy; other physical therapies may also be used concurrently and may have an 
effect. 
In addition, the analysis of these histograms provide further insights into clinical 
practice, with clinicians frequently using uterotonic therapies even when the volume 
of the blood loss is low. This demonstrates how uterotonic use in practice is often not 
linked with the standard 500 mls definition of PPH- this is important both for 
researchers and for those producing clinical guidelines. 
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Practice points 
This study suggests that PPH treatment is not usually given when 500mls volume is 
reached,but often much earlier. Whilst the PPH definition of 500mls blood loss is 
widely used, it should not be assumed that treatment is usually given at this point – 
the decision to treat seems to be based on other factors. 
Research Agenda 
1. Histograms of final blood loss, both for all woman and just those treated, should 
be used in the analysis of clinical trials to explore clinicians’ habits 
2. Studies should explore what factors (other than blood loss volume) influence 
clinicians to commence treatment 
3. In future research studies into PPH treatment, treatment should be administered 
when clinicians would normally give it, not at a pre-specified volume. 
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Figure Legend 
 
Figure 1. Histogram showing the main study results in the Chandhiok trial (9). The 
red line represents the blood loss in all participants in the methergine group. Whilst 
the blue line shows the blood loss distribution for all women included in the 
misoprostol arm,  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Figure 2. Histogram showing blood loss distributions of women in the Chandhiok trial 
(9) who were randomised to receive misoprostol. The blue line shows the distribution 
for all included women, whilst the dotted line represents the blood loss in only those 
who received treatment. 
Figure 3. Histogram showing blood loss distributions of women in the Chandhiok trial 
(9) who were randomised to receive methergine. The blue line shows the distribution 
for all included women, whilst the dotted line represents the blood loss in only those 
who received treatment. 
Figure 4. Histogram showing the main study results in the Derman trial (10). The red 
line represents the blood loss in all participants in the placebo group, whilst the blue 
line shows the blood loss distribution for all women included in the misoprostol arm 
Figure 5. Histogram showing blood loss distributions of women in the Derman trial 
(10) who were randomised to receive misoprostol. The blue line shows the 
distribution for all included women, whilst the dotted line represents the blood loss in 
only those who received treatment. 
 
 
Figure 6. Histogram showing blood loss distributions of women in the Derman trial 
(10) who were randomised to receive placebo. The blue line shows the distribution 
for all included women, whilst the dotted line represents the blood loss in only those 
who received treatment. 
Figure 7. Histogram showing the main study results in the Fawole trial (11). The red 
line represents the blood loss in all participants in the placebo group, whilst the blue 
line shows the blood loss distribution for all women included in the misoprostol arm 
Figure 8. Histogram showing blood loss distributions in women in the Fawole trial 
(11) who were randomised to receive Misoprostol. The blue line shows the 
distribution for all included women, whilst the dotted line represents the blood loss in 
only those who received treatment. 
Figure 9. Histogram showing blood loss distributions of women in the Fawole trial 
(11) who were randomised to receive placebo. The blue line shows the distribution 
for all included women, whilst the dotted line represents the blood loss in only those 
who received treatment. 
Figure10. Histogram showing the main study results of the Hofmeyr trial (12). The 
red line represents the blood loss in all participants in the placebo group, whilst the 
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blue line shows the blood loss distribution for all women included in the misoprostol 
arm 
Figure 11. Histogram showing blood loss distributions in women in the Hofmeyr trial 
(12) who were randomised to receive placebo. The blue line shows the distribution 
for all included women, whilst the dotted line represents the blood loss in only those 
who received treatment 
Figure 12. Histogram showing blood loss distributions in women in the Hofmeyr trial 
(12) who were randomised to receive misoprostol. The blue line shows the 
distribution for all included women, whilst the dotted line represents the blood loss in 
only those who received treatment 
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Table (1) included study details 
 
 
Study Participants- risk to 
PPH 
Study type Setting Prophylaxis received PPH definition and  measurement 
Chandhiock, 2006 
(9) 
1200 – low risk RCT At 30 peripheral 
health centres 
from 5 states in 
India 
Intervention: 600 mcg of oral 
misoprostol (600)  
Control: (600) an intramuscular 
injection of 0.2 mg of methergine 
(88.5%) + oral tablet of 0.125 mg 
methergine (9.7%) 
PPH was defined as > 500ml bleeding and a 
calibrated blood collection drape (BRASS-Drape) 
was used to measure blood loss for 1hour after 
delivery (and for 2 hours if bleeding persist)  
Derman, 2006 (10) 1620- low risk RCT At four primary-
health centres 
areas in rural 
India 
Intervention: A single oral dose of 
600 mcg of misoprostol (812) 
 
Control: Placebo (808) 
PPH was defined as ≥ 500 ml bleeding and  was 
assessed using a polyurethane blood collection 
drape  for 1hour after delivery (and for 2 hours if 
bleeding persist) 
Fawole,  2011 (11) 1345- not specified RCT At 6 hospitals in 
Nigeria 
Intervention: A sublingual dose of 
400 mcg of misoprostol(672) 
Control: A placebo (673), in 
addition to standard active 
management of the third stage of 
labour (oxtocine or ergometrine)  
PPH was defined as ≥ 500 ml bleeding and was 
assessed using a low-profile plastic bedpan for a 
period of 1 hour  
Hofmeyr, 2011(12) 1103- not specified RCT Gynuity health 
project and 4 
hospitals in South 
Africa, Uganda, 
and Nigeria 
Intervention: A sublingual dose of 
400 mcg of misoprostol (547)  
Control:  A placebo (556), in 
addition to standard active 
management of the third stage of 
labour (oxtocine or ergometrine) 
PPH was defined as ≥ 500 ml bleeding and was 
assessed using a low-profile plastic bedpan for a 
period of 1 hour or until bleeding stop 
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Table (2) study outcomes 
 
*Data of blood loss was available for 2 women only 
Study Number of women with PPH uterotonic given  Additional intervention used Maternal mortality 
Chandhiock, 2006 
(9) 
Total: 9 
Intervention: 4 (0.7%) 
Control: 5 (0.8%) 
Total: 6 
Intervention: 4 
Control: 2 
Type: Methergine and 
oxytocin injection 
 Manual removal of placenta (30 women in the methergine 
group) 
 One woman in the intervention group lost > 1000 mL of 
blood. Uterine exploration was carried out and a blood 
transfusion administered 
No maternal mortality 
was reported 
Derman, 2006 (10) Total: 149 
Intervention: 52 (6.4%) 
Control: 97 (12.0%) 
Total: 10 
Intervention: 3* 
Control: 6 
Type: Methergine, oxytocin  
and carboprost injection 
 One in the intervention group and 8 in the placebo arm 
had surgical intervention (repair of perineal, cervical, and 
high vaginal lacerations, manual removal of placenta) 
 One women in the placebo group received bimanual 
uterine compression alongside medical treatment 
There was one non-
haemorrhage related 
maternal death in the 
placebo group. 
Fawole,  2011(11) Total: 82 
Intervention: 40 (6.08%) 
Control: 42 (6.36%) 
Total:  
Intervention: 162 
Control: 97 
Type: Methergine and 
oxytocin injection 
 Manual placenta removal (23 in misoprostol group, 27 in 
placebo group) 
There was no death in 
either group 
Hofmeyr, 2011 (12) Total: 57 
Intervention: 22 
Control: 35 
Total: 58 
Intervention: 31 
Control: 27 
Type: : Methergine oxytocin  
and syntometrine injection 
 Manual placenta removal (32 in misoprostol group, 33 in 
placebo group) 
There was no death in 
either group 
Practice points 
This study suggests that PPH treatment is not usually given when 500mls volume is 
reached,but often much earlier. Whilst the PPH definition of 500mls blood loss is 
widely used, it should not be assumed that treatment is usually given at this point – 
the decision to treat seems to be based on other factors. 
 
 
*Practice Points
Research Agenda 
1. Histograms of final blood loss, both for all woman and just those treated, should 
be used in the analysis of clinical trials to explore clinicians’ habits 
2. Studies should explore what factors (other than blood loss volume) influence 
clinicians to commence treatment 
3. In future research studies into PPH treatment, treatment should be administered 
when clinicians would normally give it, not at a pre-specified volume. 
 
*Research Agenda
Highlight of the review  
The findings from the analysis of histograms from 4 studies with measured blood 
loss do not support its routine use to assess the efficiency of uterotonic therapy. 
However, histograms show how clinicians frequently use uterotonic therapies prior to 
the usual definition of PPH (500mls blood loss). Clinicians’ clinical concerns appear 
to be only partially based on volume of loss, and uterotonic use not linked with the 
standard 500 mls definition of PPH. 
 
*Highlights (for review)
 misoprostol for prophylaxis and treated with uterotonic.The first peak was at a total blood 
loss 600-900 ml and the other was at 1200-1300 ml (Figure 3). 
  
 
 
 
Figure 1. Histogram showing the main study results in the Chandhiok trial (9). The red 
line represents the blood loss in all participants in the methergine group. Whilst the 
blue line shows the blood loss distribution for all women included in the misoprostol 
arm,  
 
 
 
 
 
 
Figure 2. Histogram showing blood loss distributions of women in the Chandhiok trial 
(9) who were randomised to receive misoprostol. The blue line shows the distribution 
for all included women, whilst the dotted line represents the blood loss in only those 
who received treatment. 
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Figure 3. Histogram showing blood loss distributions of women in the Chandhiok trial 
(9) who were randomised to receive methergine. The blue line shows the distribution for 
all included women, whilst the dotted line represents the blood loss in only those who 
received treatment 
 
 
 
 
 
 
Figure 4. Histogram showing the main study results in the Derman trial (10). The red 
line represents the blood loss in all participants in the placebo group, whilst the blue 
line shows the blood loss distribution for all women included in the misoprostol arm 
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Figure 5. Histogram showing blood loss distributions of women in the Derman trial (10) 
who were randomised to receive misoprostol. The blue line shows the distribution for all 
included women, whilst the dotted line represents the blood loss in only those who 
received treatment. 
 
 
 
 
 
 
 
Figure 6. Histogram showing blood loss distributions of women in the Derman trial (10) 
who were randomised to receive placebo. The blue line shows the distribution for all 
included women, whilst the dotted line represents the blood loss in only those who 
received treatment. 
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 Figure 7. Histogram showing the main study results in the Fawole trial (11). The red 
line represents the blood loss in all participants in the placebo group, whilst the blue line 
shows the blood loss distribution for all women included in the misoprostol arm 
 
Figure 8. Histogram showing blood loss distributions in women in the Fawole trial (11) 
who were randomised to receive Misoprostol. The blue line shows the distribution for 
all included women, whilst the dotted line represents the blood loss in only those who 
received treatment. 
 
 
  
 
 
 
 
 
Figure 9. Histogram showing blood loss distributions of women in the Fawole trial (11) 
who were randomised to receive placebo. The blue line shows the distribution for all 
included women, whilst the dotted line represents the blood loss in only those who 
received treatment. 
 
 
Figure 10. Histogram showing the main study results of the Hofmeyr trial (12). The red 
line represents the blood loss in all participants in the placebo group, whilst the blue 
line shows the blood loss distribution for all women included in the misoprostol arm 
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 Figure 11. Histogram showing blood loss distributions in women in the Hofmeyr trial 
(12) who were randomised to receive placebo. The blue line shows the distribution for 
all included women, whilst the dotted line represents the blood loss in only those who 
received 
treatment
 
Figure 12. Histogram showing blood loss distributions in women in the Hofmeyr trial 
(12) who were randomised to receive misoprostol. The blue line shows the distribution 
for all included women, whilst the dotted line represents the blood loss in only those 
who received treatment 
 
 
MCQ relating to postpartum haemorrhage 
Question 1 
A blood loss histogram: 
A. shows the proportion of women with a postpartum haemorrhage in a study 
B. shows the speed women’s blood loss  
C. shows the number (or proportion) of women with various levels of blood loss 
D. can show the volume of blood loss at the time when study participants received 
treatment 
Answer to question 1 
(A)  F    (B) F     (c) T   (d) F 
Explanation: 
A blood loss histogram is created to show the number (or proportion) of women at 
each level of final blood loss. It cannot show how rapidly women reached that final 
rate. Whilst you can analyse those who received treatmentseparately (as in this 
study), you cannot assume that they stopped bleeding immediately after treatment. 
The histogram therefore shows the final blood loss, not the loss when the treatment 
was given.  
To calculate the rate of blood loss over a certain volume (eg 500mls or 1000mls), 
you would need to measure the area under the curve after that blood loss increment. 
You cannot read the proportion off the graph directly. 
 
*MCQs
Question 2 
According to the histograms analysed in this study: in most women, the first dose of 
uterotonic treatment for PPH is given  
A. when the blood loss is over 500mls 
B. Virtually all women with blood loss over 500mls receive uterotonic treatment 
C. Uterotonic treatment is commonly given before the blood loss volume reaches 
300mls 
Answer to question 2 
(A)  F    (B) F     (c) T 
Explanation 
Although postpartum blood loss was objectively measured in all of included studies, 
many women receiving uterotonic treatment had blood loss under 500mls whilst 
those with large blood loss volumes received no treatment.   
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Dear Beverly Burns, 
Re: The Use Of  Histograms To Assess The Efficacy Of Uterotonic Treatment For Postpartum 
Haemorrhage: A Feasibility Study. 
Please find attached a study to be considered for publication in the Elsevier 
The initial treatment of PPH has largely been dependant on uterotonics. This paper examined the 
use of histograms to assess the efficacy of uterotonic treatment for PPH. The findings from this 
study do not support the routine use of histogram analysis to assess the efficiency of uterotonic 
therapy. The paper provides further insights into clinical practice, with clinicians frequently using 
uterotonic therapies even when the volume of the blood loss is low. This demonstrates how 
uterotonic use in practice is often not linked with the standard 500 mls definition of PPH. 
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Yours faithfully, 
 
Dr. Aflaifel  
Dr. Nasreen Afalifel MBCHB MSc PhD 
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Crown Street 
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Re: The Use Of Histograms To Assess The Efficacy Of Uterotonic Treatment For 
Postpartum Haemorrhage: A Feasibility Study 
Dear Elsevier Editor  
. 
Thank you for revising our paper on” Third stage blood loss histogram”.  Most of the 
revisions prompted by the reviewers’ comments are minor and require no further 
explanation than what appears in my responses below. 
I made the requested changes to the manuscript and added the reference to the 
tables as well. I also checked the revised manuscript to that it is within the word limit 
and correctly formatted. 
We hope the revised manuscript will better suit the Best Practice & Research Clinical 
Obstetrics & Gynecology but are happy to consider further revisions, and we thank 
you for your continued interest in our research. 
 
Yours sincerely  
Dr Aflaifel 
Dr. Nasreen Afalifel MBCHB MSc PhD 
Department of Women’s and Children’s 
Health 
Liverpool Women’s Hospital 
Crown Street 
Liverpool 
L8 7SS 
E: nasreen.aflaifel@gmail.com 
 
*Detailed Response to Reviewers
